Object. After traumatic brain injury (TBI), S100B protein is released by astrocytes. Furthermore, cerebrospinal fluid (CSF) and serum S100B levels have been correlated to outcome. Given that no data exist about the temporal profile of cerebral S100B levels following TBI and their correlation to serum levels, the authors examined whether proton magnetic resonance (MR) spectroscopy is capable of measuring S100B.
EASUREMENT of the S100B protein as an early biochemical marker of the severity of brain damage is becoming more frequently performed in patients who have incurred TBI because serum S100B levels have been found to be a predictor of the consequent prognosis. 11, 26, 27 Nonetheless, the correlation between high serum S100B levels and poor outcome following TBI seems to contradict the well-demonstrated beneficial effect of exogenously administered intraventricular S100B on cognitive function. 18, 24, 25 The S100B protein belongs to a multigenic family of low molecular weight (9-13 kD) calcium-binding S100 proteins 7, 10 predominately abundant in astrocytes 8 and constituting 1 to 1.5 g/mg soluble protein in the brain. 23 Experimental data demonstrate a neuroprotective and neurotrophic effect of the S100B protein, which is involved in signal transduction as well as regulation of enzyme activity and calcium homeostasis, 35, 41, 44 stimulation of neurite outgrowth, and enhancement of cell maintenance. 2, 19, 42 Note that S100B is actively secreted from astroglia 36, 39, 40 and its release has been found to occur in cultured astrocytes within a few minutes after receptor activation, lasting for up to 10 hours. 4 Data from additional investigations have confirmed the dose-dependent action of S100B, showing a beneficial effect on neurons at physiological nanomolar concentrations. 15, 22, 32 In contrast, at micromolar concentrations, enhanced nitric oxide generation occurs, potentially leading to cell death. 14, 28 Many authors have reported that elevated serum levels of the S100B protein in head-injured patients correlate with a poor outcome. 11, 29, 30 On the other hand, serum S100B levels are normally high directly after TBI, but become normalized by 24 hours postinjury in a high percentage of cases, even in those with a bad outcome. 17 Results from another study in head-injured patients demonstrated a delayed increase in serum S100B levels after Day 6 posttrauma, which was correlated to outcome, and attributed these findings to secondary brain cell damage. 30 Whether elevated serum S100B levels following TBI or other brain insults are simply due to an increased passage from the central nervous system through a compromised BBB or are truly reflective of increased astrocytic production of S100B in response to trauma has yet to be investigated. Furthermore, there are no data about cerebral S100B levels and their correlation to serum and CSF levels. Because proton MR spectroscopy is an easily accessible tool for identifying cerebral metabolites like NAA, creatine, phosphocreatine, and choline, we attempted to determine whether MR spectroscopy is capable of noninvasively detecting increased cerebral S100B levels after TBI and to correlate these data to serum levels.
Materials and Methods

Animals and Surgical Procedure
The animal studies were conducted with the approval of the Institutional Animal Care and Use Committee and National Institutes of Health guidelines. Experiments were performed in 250-to 300-g adult male Sprague-Dawley rats. Surgery was performed after intubation with the rats placed in a state of isoflurane anesthesia and receiving controlled ventilation. A 4.9-mm craniotomy was trephined halfway between the lambda and bregma over the left hemisphere for FPI. Screws were inserted into the holes rostral and lateral to the craniotomy for stability, and a Luer-Loc hub made from the plastic end of a 20-gauge needle was cemented into the craniotomy by using dental cement. A fluid-percussion pulse of 2.09 Ϯ 0.03 atm was administered through the craniotomy onto the intact dura mater by an FPI device. 6 After the percussion pulse, the Luer-Loc hub was removed. Animals subjected to intraventricular infusion were placed in a stereotactic frame and fitted with a brain infusion cannula (3-5 mm, Alzet brain infusion kit; DURECT Corp., Cupertino, CA). The cannula was implanted according to the atlas of Paxinos and Watson 26 with the tip aimed at the left lateral ventricle (stereotactic coordinates 0.8 mm behind the bregma, 1.5 mm lateral to the midline, 3-4 mm beneath the surface of the skull). Using dental cement, we secured the cannula to two stainless-steel screws inserted into holes made rostral and lateral. A microosmotic pump (Alzet model 1007D; DURECT Corp.) filled with a 90-l infusion volume kept at 37˚C was implanted subcutaneously in the neck and connected to the infusion cannula. After sutures were completed, anesthesia was discontinued and the animals were returned to the animal facility.
Proton MR Spectroscopy
Proton MR spectroscopy experiments were performed using a 2.35-tesla, 40-cm bore magnet (Bruker Instruments, Billerica, MA) equipped with an actively shielded gradient insert (12-cm inner diameter, maximum gradient strength 25 G/cm). Radiofrequency excitation/reception was performed using an actively decoupled radiofrequency coil set consisting of a birdcage design resonator (7-cm inner diameter) and a surface coil (2-cm diameter). Proton spectroscopy was performed using a water-suppressed spin echo voxel-localization technique (PRESS sequence).
In Vitro Proton MR Spectroscopy Studies
To determine whether proton MR spectroscopy is capable of detecting any S100B signal, in vitro experiments were performed using 10-nM, 100-nM, and 1-M S100B concentrations (purified bovine S100B protein; Calbiochem, La Jolla, CA) diluted in PBS containing 10% rat serum albumin. After results of these in vitro experiments revealed the feasibility of S100B detection by MR spectroscopy with a consistent peak at 4.5 ppm, we conducted in vivo studies to verify whether exogenously increased cerebral S100B concentrations or endogenous S100B release after TBI could be demonstrated on MR spectroscopy.
In Vivo Proton MR Spectroscopy Studies
In experimental animals, a 4 ϫ 4 ϫ 4-mm voxel was centered in each hemisphere; in control animals, a voxel of 7 ϫ 5 ϫ 5 mm was placed centrally in the brain. Spectra were acquired using a TR of 3000 msec, TE of 30 msec, and 256 acquisitions. Data were postprocessed by applying an exponential filter with line broadening of 1 Hz and zero filling from 4 to 8 ϫ 10 3 real points. Areas under the curve of the resultant peaks were manually determined and normalized both to the ipsilateral NAA peak in control animals intraventricularly infused with vehicle and to the contralateral peak in animals intraventricularly infused with S100B as well as in injured animals.
Measurement of S100B in Serum
With the rat in a state of light anesthesia, blood samples (500-l volume) were drawn from the tail vein by using preheparinized syringes (Pro-vent; Portex, Inc., Keene, NH). To avoid excessive blood loss, each animal was subjected to this procedure only once. Blood samples were immediately centrifuged for 10 minutes at 1.3 G and 4˚C. Serum samples were stored at Ϫ80˚C until the assays were performed. Analysis was conducted using a commercially available kit and an automated immunoanalyzer (chemiluminescence immunoassay on the LIAISON Sangtec 100 analyzer; Byk-Sangtec-Diagnostica, Dietzenbach, Germany). Sensitivity for the assay was 0.02 ng/ ml for S100B. Note that S100B is a well-conserved protein within species, and antibodies from a wide variety of mammalian species react with it. Purified bovine S100B is commonly used to establish standards, and the same assay is routinely used in humans and in rats. 34 
Study Protocol
The objective in these experiments was to assess whether proton MR spectroscopy is capable of detecting cerebral S100B levels increased by either exogenous intraventricular administration or endogenous release and to compare these levels with serum S100B levels. Therefore, animals were randomly assigned to the following groups: intraventricular vehicle (Group A, six rats) or S100B (Group B, six rats) infusion continuously for 5 days and subsequent MR spectroscopy, or lateral FPI and MR spectroscopy at 2 hours (Group C, eight rats) or on Day 5 (Group D, eight rats) postinjury. Purified bovine S100B protein (Calbiochem) was added to PBS containing 0.1 mg rat serum albumin/ml and was infused at a rate of 0.5 l/ hour (that is, 50 ng = 2.5-nM S100B infusion/hour). The micropumps were removed immediately before MR spectroscopy while the animal was in a state of pentobarbital anesthesia (30 mg/kg body weight). Blood samples for the measurement of S100B in serum were obtained at 2 hours posttrauma (Group A, five rats; Group C, five rats) or on Day 5 after trauma (Group B, 10 rats; Group D, 10 rats). After the experimental procedures were completed, all animals were killed using an overdose of pentobarbital.
Statistical Analysis
Commercially available software (SPSS, Inc., Chicago, IL) was used for statistical analysis. The levels of S100B in serum (nanograms per milliliter) as well as the AUC of the proton MR spectroscopy peak specific for S100B (4.6-4.3 ppm), choline (3.35-3.1 ppm), creatine (3.1-2.8 ppm), and ipsilateral NAA (2.2-1.8 ppm) were normalized to the contralateral NAA peak and analyzed using a randomized analysis of variance for group variations followed by a Tukey post hoc analysis. The correlation between the S100B concentration and the AUC of the peak on proton MR spectroscopy in the in vitro experiments was compared using a t-test. Statistical significance was set at a probability value less than 0.05.
Results
In Vitro Studies
The in vitro experiments demonstrated the feasibility of S100B detection on proton MR spectroscopy with a consistent peak at 4.5 ppm, which is close to the water peak. Normalization of the AUC of the S100B peak to the peak of the 10-nM S100B solution revealed 0.11 for the control PBS solution, 1.0 for the 10-nM S100B solution, 1.435 for the 100-nM S100B solution, and 1.939 for the 1-M S100B solution (Fig. 1A) , thereby demonstrating a significant correlation between the AUC measured on MR spectroscopy and the respective concentrations (r = 0.991, p Ͻ 0.01; Fig. 1B) .
Effect of Intraventricular Infusion of S100B on MR Spectra and Serum Levels
No procedure in this study was related to death or infection, and all animals tolerated the surgical procedures and MR spectroscopy experiments well, without any obvious side effects. The proton MR spectroscopy examinations were performed within 30 to 60 minutes. Because the S100B peak was extremely close to the water peak, S100B measurements were rejected if water suppression in the PRESS sequence was inadequate. In three vehicle-infused animals no clear S100B peak was detectable, and in one S100B-infused animal the water suppression was insufficient; thus, the MR spectroscopy data in these animals were excluded from statistical analysis. The analysis of variance revealed a significant group effect for the MR spectroscopy assessment of the ipsilateral (F 3,18 = 5.195, p = 0.009) and contralateral (F 3,10 = 5.195, p = 0.030) S100B peak as well as the serum S100B data (F 3,50 = 3.135, p = 0.021). In uninjured animals intraventricularly infused with S100B, T 2 -weighted MR images demonstrated the track of the infusion needle (Fig. 2) . The Tukey post hoc test for the AUC of the S100B peak normalized to the NAA peak indicated that intraventricular S100B infusion bilaterally increased the S100B peak significantly (Group B, five rats: ipsilateral 0.437 Ϯ 0.065, p = 0.024; contralateral 0.545 Ϯ 0.152, p = 0.025), compared with vehicle-infused animals (Group A, three rats, 0.060 Ϯ 0.022). Measurement of serum S100B in vehicle-infused animals established normal levels at 0.062 Ϯ 0.015 ng/ml, which were not altered after 5 days of intraventricular S100B infusion (0.079 Ϯ 0.015 ng/ml, not significant).
Effect of TBI on S100B MR Spectra and Serum Levels
There was no injury-induced death among the rats. Water suppression was insufficient in four animals altogether, which were excluded from statistical analysis of the MR spectroscopy data. After lateral FPI, the T 2 -weighted MR image demonstrated no relevant edema or other intracranial pathology (Fig. 3) . The Tukey post hoc tests revealed that the ipsilateral S100B peak tended to rise at 2 hours after trauma (Group C, six rats: 0.189 Ϯ 0.039, p = 0.481) and significantly increased on Day 5 postinjury (Group D, six rats: 0.405 Ϯ 0.073, p = 0.014), compared with control animals. A comparison of the AUC for the choline, creatine, and ipsilateral NAA MR spectroscopy peak revealed no intergroup differences (Table 1 ). The post hoc Tukey test of serum S100B indicated an early peak at 2 hours after injury (0.607 Ϯ 0.036 ng/ml) compared with that in control animals (0.062 Ϯ 0.015 ng/ml; p = 0.000) and normalized on Day 5 postinjury (0.067 Ϯ 0.034 ng/ml, not significant; Fig. 4 ).
Discussion
There were three new findings in this study. First, proton MR spectroscopy-both in vitro and in vivo-can demonstrate the presence of the S100B protein, showing a significant correlation between the AUC of the S100B peak measured on MR spectroscopy and the respective S100B concentration. Thus, cerebral S100B levels exogenously increased by the intraventricular S100B infusion could be exhibited noninvasively for the first time. Second, proton MR
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Assessment of S100B on proton MR spectroscopy after FPI 1117 FIG. 1. A: Proton MR spectroscopy study demonstrating spectra of different S100B concentrations. In vitro experiments to assess a correlation of the S100B concentration revealed an S100B-specific peak at 4.5 ppm, which was close to water's peak. B: Graph illustrating the AUC of the proton MR spectroscopy peak for different S100B concentrations normalized to the peak of the 10-nM S100B solution. Note the significant correlation (r = 0.991, p Ͻ 0.01).
spectroscopy displayed increased endogenous S100B levels as soon as 2 hours after TBI and even up to Day 5 postinjury. Third, the cerebral S100B levels detected on proton MR spectroscopy do not correlate with the serum S100B levels measured at corresponding time points, thereby indicating that S100B release into the blood is modulated by additional factors, such as the integrity of the BBB, cerebral blood flow, and possibly degradation and sequestration by other organs.
Feasibility of the Assessment of S100B on Proton MR Spectroscopy
To identify whether proton MR spectroscopy was capa-A. Kleindienst, et al.
FIG. 3. Proton MR spectroscopy (A) and MR imaging (B) results after lateral FPI. On Day 5 after FPI, the T 2 -weighted MR image revealed no relevant edema or other intracranial pathology.
White boxes indicate the region of interest (RoI) from which the subsequent spectra were acquired. On proton MR spectroscopy, an S100B-specific peak at 4.5 ppm (close to the water peak) is depicted, although it cannot be found in association with vehicle-infused animals (spectra of the ipsilateral side).
FIG. 2. Proton MR spectroscopy (A) and MR imaging (B) results after intraventricular S100B infusion. A T 2 -weighted MR image demonstrating the track of the infusion needle (B, arrow).
A proton MR spectroscopy image exhibiting a S100B-specific peak at 4.5 ppm, which is not found in vehicle-infused animals (A, spectra of the ipsilateral side).
ble of demonstrating any S100B signal, in vitro experiments were performed using different concentrations of S100B diluted in PBS containing 10% rat serum albumin, ranging from lowest normal (0.001 nM = 0.02 ng/ml) to high supranormal levels (1 M = 20 g/ml). After these in vitro experiments revealed the feasibility of S100B detection on proton MR spectroscopy with a consistent peak at 4.5 ppm, which is close to the water peak, and demonstrated a significant positive correlation between the S100B concentration and the AUC measured on MR spectroscopy, we conducted in vivo studies to verify whether exogenously increased cerebral S100B concentrations or endogenous S100B release after TBI can be demonstrated on MR spectroscopy.
Assessment of Exogenously Administered S100B on Proton MR Spectroscopy
Because the underlying mechanism of S100B passage through the BBB has not been clarified and no data exist about cerebral S100B levels and their correlation to serum and CSF levels, we compared normal and exogenously increased cerebral S100B levels measured on MR spectroscopy with the respective serum levels in the context of an intact BBB. To increase the cerebral S100B concentrations we chose intraventricular infusion as the route of administration; in its transfer through the extracellular fluid, S100B has been found to affect hippocampal function. 18 Furthermore, horseradish peroxidase, a protein with a molecular weight of 40 kD, is rapidly transferred from the CSF to the extracellular fluid of different brain regions. 31 The 20-kD S100B protein is also supposed to be transferred.
For 5 days, we infused S100B at a concentration of 50 g/ml and an infusion rate of 0.5 l/hour (2.5 nM/hour) into the lateral ventricle. Assuming a CSF distribution volume of 250 l and an hourly clearance of 25%, the CSF S100B concentration reached 200 ng/ml (10 nM). These levels are 100 times greater than normal (Ͻ 0.2 ng/ml in control volunteers to 0.8 ng/ml in older individuals) and exceed by up to 10 times the upper serum levels that occur in traumatic pathologies.
9,27,29 After 5 days of intraventricular S100B infusion, the S100B peak increased significantly in the hemisphere ipsilateral as well as the one contralateral to the infusion site, thereby verifying bilateral S100B distribution. Given that serum S100B levels remained normal, any relevant contribution of increased cerebral S100B levels to the respective blood concentrations appeared to be ruled out. These findings provided evidence that even high cerebral S100B levels may not pass through an intact BBB.
Assessment of S100B Release Into Serum After Experimental TBI
Analysis of serum S100B in our study revealed signif-
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Assessment of S100B on proton MR spectroscopy after FPI * The AUC of the different peaks depicted on proton MR spectroscopy of the ipsilateral and contralateral side are normalized to the AUC of the ipsilateral NAA peak in control animals infused with vehicle and of the contralateral peak in the other groups, respectively. Compared with that for control animals infused with vehicle, the AUC of the S100B peak increased in both ipsilateral and contralateral sides after intraventricular S100B infusion (p Ͻ 0.05). Two hours after a lateral FPI, the AUC of the S100B peak started increasing and was on Day 5 after injury significantly higher than that for control animals (p Ͻ 0.05). The AUC of the choline, creatine, or ipsilateral NAA did not differ between the groups. Values represent the means Ϯ SEM. Abbreviations: NS = not significant; --= not applicable.
1119
† Tukey post hoc analysis.
FIG. 4.
Bar graph depicting the results of a comparison of cerebral S100B levels assessed on proton MR spectroscopy and S100B serum levels in different groups. The serum levels of S100B (ng/ml, mean Ϯ SEM) and the AUC of the S100B peak on proton MR spectroscopy (mean Ϯ SEM) were assessed in control animals infused with vehicle (control), after 5 days of intraventricular S100B infusion (S100B icv), and 2 hours (2hr post-injury) and 5 days (d5 postinjury) after lateral FPI. Asterisk indicates statistical significance compared with control animals.
icantly increased levels as early as 30 minutes after FPI, peaking at 2 hours and thereafter rapidly returning to basal levels. Our findings are in agreement with those in other clinical studies showing an increase in serum S100B early after different brain insults, indicating an immediate release of cerebral S100B into the blood. 16, 43 Similarly, following stretch injury in hippocampal cell cultures or cortical impact injury in rats, serum S100B levels were elevated for 24 hours. 34, 37 Although high serum S100B levels have been correlated to a worse outcome after TBI, clinical studies have revealed conflicting data. Although there is no doubt about the significance of elevated serum S100B levels within 24 hours post-TBI as an adverse prognostic factor, the relevance of longer-lasting increased levels and their correlation to outcome is still under discussion. 3, 5, 11, 12, 17, 29, 30 On the other hand, in neurodegenerative, inflammatory, and psychiatric diseases, increased S100B levels have also been found. 33, 38 These inconsistent findings may be due to the highly variable pattern of injuries commonly seen in clinical studies as well as the variability of secondary injury. On the other hand, the correlation between high serum S100B levels and a worse outcome seems to contradict the beneficial effect of intraventricularly administered S100B on cognitive function, which we and others have demonstrated experimentally.
18,24,25
Assessment of Endogenously Released S100B on Proton MR Spectroscopy After Experimental TBI
After lateral FPI, the T 2 -weighted MR image demonstrated no relevant cerebral edema, whereas proton MR spectroscopy revealed an S100B peak as early as 2 hours after injury. On Day 5 postinjury, the S100B peak was even more increased and differed significantly from those in controls. Because neither the underlying mechanism of S100B passage through the BBB nor the relative contribution of astrocytic death, stimulated release, or BBB opening to serum levels has been clarified yet, we compared cerebral S100B levels measured on MR spectroscopy and the respective serum levels.
Given that the temporal profile of S100B serum levelsincreasing immediately after FPI, peaking at 2 hours postinjury, and afterward promptly returning to normal values at 24 hours postinjury-parallels the BBB disruption occurring after experimental TBI, the passage of cerebral S100B into the blood seems to be a function mainly of BBB integrity. We could feasibly perform MR spectroscopy at only two time points after FPI, thereby not allowing the assessment of a complete profile of endogenous S100B release. Nevertheless, MR spectroscopy revealed slightly enhanced cerebral S100B levels 2 hours after FPI and significantly increasing levels thereafter to more than twice these values by Day 5 postinjury, thus supporting the hypothesis that S100B is actively secreted from astroglia. 4, 36, 39, 40 We and others have speculated that S100B is involved in an endogenous repair mechanism to overcome brain damage after injury. 1, 18 On the other hand, the very rapid occurrence of high serum S100B levels immediately after injury may represent the contribution of intracellular S100B originating from damaged astrocytes and passing through an impaired BBB for a limited time.
Implication of Experimental Findings on Assessment of Prognosis After TBI
The majority of experimental data demonstrate a neuroprotective and neurotrophic effect of the S100B protein, 2, 19, 35, 41, 42, 44 and S100B has been associated with synaptic remodeling, promotion of neural plasticity, and improved cognitive performance and memory function. 1, 18, 20, 24, 25 Cognitive impairment is still one of the most disabling features following TBI and often longlasting behavioral sequelae occur, including decreased memory recall, slower processing of ideas, and increased irritability. 13, 21 A reliable method of estimating the endogenous restoration of these deficits would allow us to predict prognosis and thereby assist the treating physician in helping to protect the patient's socioeconomic position and making better plans for the subsequent reintegration and rehabilitation processes. The assessment of cerebral S100B levels by using proton MR spectroscopy may thus offer a method of monitoring endogenous repair mechanisms essential for cognitive recovery after brain insults rather than merely demonstrate the extent of initial brain damage and consecutive BBB disruption, as serum S100B levels have been assumed to do.
Conclusions
Data from the current study-the first undertaken to demonstrate the feasibility of assessing cerebral S100B levels by performing proton MR spectroscopy-revealed increased endogenous S100B levels lasting up to Day 5 after experimental TBI. More importantly, we demonstrated that proton MR spectroscopy may represent an easily accessible tool for noninvasively identifying increased cerebral S100B levels and thus understanding its biology better. We therefore assert that proton MR spectroscopy may be a more reliable method of predicting prognosis after TBI than measuring serum S100B levels. Additional studies are needed to compare MR spectroscopy with outcome and other parameters, such as NAA levels.
